Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CRHR1 | P34998 | 14/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propane SCHEMBL10920887 | 0.87 | KMT2A (0.49) | KMT2AMEN1CRHR1KDM4EHTT | |
| SCHEMBL1603021 | 0.82 | KMT2A (0.67) | KMT2AMEN1CRHR1KDM4EHTT | |
| SCHEMBL12250813 | 0.79 | KMT2A (0.44) | KMT2AMEN1CRHR1KDM4ELMNA | |
| SCHEMBL12483305 | 0.78 | KMT2A (0.49) | KMT2AMEN1CRHR1KDM4EHTT | |
| SCHEMBL10849722 | 0.77 | KMT2A (0.51) | KMT2AMEN1CRHR1KDM4EHTT | |
| SCHEMBL432253 | 0.77 | MEN1 (1.00) | KMT2AMEN1KDM4EHTTLMNA | |
| SCHEMBL30336057 | 0.77 | MEN1 (1.00) | KMT2AMEN1KDM4EHTTLMNA | |
| SCHEMBL11515908 | 0.76 | CRHR1 (0.44) | KMT2ACRHR1KDM4ELMNACYP1A2 | |
| SCHEMBL1425326 | 0.76 | KMT2A (0.59) | KMT2AMEN1CRHR1KDM4EHTT | |
| SCHEMBL12485791 | 0.76 | KMT2A (0.46) | KMT2AMEN1CRHR1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078165-B2 | Compounds for treating tuberculosis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2021-08-03 | — | — | US | disclosed |
| US-11078165-B2 | Compounds for treating tuberculosis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2021-08-03 | — | — | US | disclosed |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-07-23 | — | — | US | disclosed |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-07-23 | — | — | US | disclosed |
| WO-2018151681-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2018-08-23 | — | — | WO | disclosed |
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2257541-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | HOFFMANN-LA ROCHE INC. (US) | 2013-07-25 | — | — | US | disclosed |
| CN-101952275-A | Modulators for amyloid beta | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| EP-2257541-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
| US-4416885-A | MUSCULAR DISORDERS | SOCIETE D'ETUDES DE PRODUITS CHIMIQUES (FR) | 1983-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078165-B2 | Compounds for treating tuberculosis | ATP5ME, ATP5MG, ATP5F1D | KMT2A 2920/4885MEN1 4589/4885CRHR1 4648/4885 |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | ATP5ME, ATP5MG, ATP5F1D | KMT2A 2920/4885MEN1 4589/4885CRHR1 4648/4885 |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | KMT2A 2755/4885MEN1 1852/4885CRHR1 4180/4885 |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | APP, PSEN1, APOB | KMT2A 2670/4885MEN1 1873/4885CRHR1 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.